Table 2.
Summary of the correlation of TRIP13 expression and clinical outcomes.
| Tumor | The correlation of TRIP13 expression and OS | P Value |
|---|---|---|
| Adrenocortical carcinoma | Negative | 1 * 10−8 |
| Breast invasive carcinoma | NS | 0.11 |
| Cervical squamous cell carcinoma and endocervical adenocarcinoma | NS | 0.69 |
| Cholangio carcinoma | NS | 0.6 |
| Colon adenocarcinoma | NS | 0.18 |
| Lymphoid Neoplasm Diffuse Large B-cell Lymphoma | NS | 0.71 |
| Esophageal carcinoma | NS | 0.9 |
| Glioblastoma multiforme | NS | 0.24 |
| Head and Neck squamous cell carcinoma | NS | 0.94 |
| Kidney Chromophobe | Negative | 0.012 |
| Kidney renal clear cell carcinoma | Negative | 0.0085 |
| Kidney renal papillary cell carcinoma | Negative | 0.00015 |
| Acute Myeloid Leukemia | NS | 0.24 |
| Brain lower grade Glioma | Negative | 2.9 * 10−5 |
| Liver hepatocellular carcinoma | Negative | 2 * 10−4 |
| Lung adenocarcinoma | Negative | 0.001 |
| Lung squamous cell carcinoma | NS | 0.46 |
| Mesothelioma | Negative | 1.3 * 10−6 |
| Ovarian serous cystadenocarcinoma | Negative | 0.0076 |
| Pancreatic adenocarcinoma | Negative | 0.04 |
| Pheochromocytoma and Paraganglioma | NS | 0.17 |
| Prostate adenocarcinoma | NS | 0.74 |
| Rectum adenocarcinoma | NS | 0.94 |
| Sarcoma | NS | 0.063 |
| Skin Cutaneous Melanoma | Negative | 0.036 |
| Stomach adenocarcinoma | NS | 0.99 |
| Testicular Germ Cell Tumors | NS | 0.33 |
| Thyroid carcinoma | NS | 0.36 |
| Thymoma | Negative | 0.048 |
| Uterine Corpus Endometrial Carcinoma | NS | 0.75 |
| Uterine Carcinosarcoma | NS | 0.73 |
| Uveal Melanoma | NS | 0.55 |